IGI Logo

Abbott India Ltd reported a 9.5% jump in fourth-quarter profit on Friday, helped by strong sales in its mainstay pharmaceuticals segment.

Profit for the company, which makes ibuprofen pain-reliever under the brand name Brufen, rose to 2.31 billion rupees ($28.3 million) in the three months ended March 31, from 2.11 billion rupees a year ago, the company said in an exchange filing.

For further results highlights, click

WHY IT MATTERS

Abbot India, for which pharmaceutical is the sole revenue generator, develops and distributes over 600 products in India, including vitamins, anti-allergic drugs and consumer care. The local unit of U.S. healthcare company Abbott Laboratories reported double-digit growth in net income in the last two quarters, helped by a steady decline in operating expenses.

Earlier this week, rival Pfizer Ltd reported a 3.1% increase in fourth-quarter profit on lower raw material expenses, while GlaxoSmithKline Pharmaceuticals Ltd posted an 8.6% fall in pre-tax profit.

PEER COMPARISON

Estimates Analysts' sentiment

(next 12

months)

RIC PE EV/EBI Revenue Profit Mean # of Stock to Div

TDA growth growth rating* analyst price yield

s target** (%)

Abbott 41.03 28.85 11.68 15.11 Buy 9 1.00 0.68

India

Ltd

Pfizer 27.20 17.91 6.57 4.01 Buy 6 0.84 0.92

Ltd

GlaxoSm 30.93 23.34 7.07 5.33 Buy 7 0.96 2.32

ithKlin

e

Pharmac

eutical

s Ltd

Cipla 21.10 11.89 10.02 15.28 Buy 40 0.87 0.92

Ltd

* Mean of analysts' ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell

** Ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT

JAN-MARCH STOCK PERFORMANCE

-- All data from Refinitiv

-- $1 = 81.7800 Indian rupees